FeesSafety
Pluang+

OneMedNet expands reach with 13th partner to combine clinical data and AI patient-journey analytics.

Market News
09 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
OneMedNet expands reach with 13th partner to combine clinical data and AI patient-journey analytics.

OneMedNet announced its 13th channel partnership with an AI healthcare intelligence company to resell its first-party multimodal clinical data combined with the partner's extensive patient journey data. This collaboration enhances data depth and breadth, supporting AI model training, clinical development, and real-world evidence generation. The partnership has already boosted OneMedNet's sales funnel by about 25%, marking its third AI-focused channel partner and reinforcing its strategy of direct data control and regulatory-grade de-identification. This move positions OneMedNet to better serve healthcare AI and pharmaceutical research markets with comprehensive, high-quality real-world data.

OneMedNet's new AI healthcare data partnership provides context for readers following health-sector stocks on Pluang. As of Nov 09, 2026 19:41 WIB, out of 150 priced US health-sector stocks, 121 rose and 18 fell. Inovio Pharmaceuticals Inc (INO) gained 8.64% to USD 1.32 with a typical hold time of 41 days, contrasting with LifeStance Health Group Inc. (LFST), which dropped 5.66% to USD 12.99 and has a shorter typical hold time of 12 days.

More News

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...

Market News
Neutral
1 hour ago
New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...

Company Fundamentals
Bullish
2 hours ago
Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...

Bearish
2 hours ago
Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...

Market News
Bullish
2 hours ago
ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App